AstraZeneca PLC

Change company Symbol lookup

Select an option...

AZN AstraZeneca PLC

AFAQU AF Acquisition Corp

PTON Peloton Interactive Inc

ETR Entergy Corp

ACMR ACM Research Inc

RGAGX American Funds The Growth Fund of America® Class R-6

ATRC AtriCure Inc

CTRA Coterra Energy Inc

CINF Cincinnati Financial Corp

ATOM Atomera Inc

Go

--TOPAZ-1 Phase III trial subgroup analysis showed the addition of IMFINZI to standard-of-care chemotherapy improved overall survival benefit in patients with advanced biliary tract cancer regardless of primary tumor location (BusinessWire)

Positive high-level results from a planned interim analysis of the AEGEAN Phase III trial showed treatment with AstraZeneca's IMFINZI(R) (durvalumab) in combination with neoadjuvant chemotherapy before surgery demonstrated a statistically...(BusinessWire)

--In Wilson disease, excess copper build-up in organs and tissues can lead to liver disease as well as neurological and psychiatric symptoms Detailed results from the positive FoCus Phase III trial in Wilson disease showed that ALXN1840, an...(BusinessWire)

Results from the PROpel Phase III trial showed that LYNPARZA(R) (olaparib), jointly developed and commercialized by AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, in combination with abiraterone significantly improved...(BusinessWire)

Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis' eplontersen met its co-primary endpoints in a planned interim...(BusinessWire)

FinancialNewsMedia.com News Commentary According to the World Health Organization, top global killers include heart failure, COPD, cancers, Alzheimer's, neonatal conditions, and diabetes. Therefore, discovering viable treatments for these issues is...(PR Newswire)

--ENHERTU met the primary endpoint of progression-free survival in patients with HR-positive disease, reducing the risk of disease progression or death by 49% vs. chemotherapy --ENHERTU is the first HER2-directed therapy to demonstrate a survival...(BusinessWire)

Updated results from the ELEVATE-TN Phase III trial showed AstraZeneca's CALQUENCE(R) (acalabrutinib) maintained a statistically significant progression-free survival (PFS) benefit versus chlorambucil plus obinutuzumab and a safety and tolerability...(BusinessWire)

The first patients have been dosed in the IRIS Phase III clinical trial of anifrolumab in lupus nephritis (LN). Up to 60% of patients with lupus develop kidney involvement. In more severe cases, this can develop into LN.(1) LN is characterized by...(BusinessWire)

--Results from multiple trials further reinforce strength of industry-leading portfolio and pipeline, including novel combinations, across cancers with high unmet need AstraZeneca advances its ambition to redefine cancer care with new data to be...(BusinessWire)

--MANDALA Phase III trial results published in the New England Journal of Medicine and presented at ATS 2022 International Conference Full results from the positive MANDALA Phase III trial showed that PT027 (albuterol/budesonide) at two different...(BusinessWire)

EQNX::TICKER_START (NYSE:ATHM),(NasdaqGM:LIZI),(NasdaqGM:QH),(NYSE:KUKE),(Other OTC:CLCGY),(Other OTC:BOSSY),(NYSE:FPAFY),(Other OTC:TPRKY),(NASDAQ:GRFS),(NASDAQ:HCM),(NASDAQ:HYW),(NYSE:COE),(NASDAQ:AZN),(Other OTC:EDPFY),(Boerse Frankfurt...(Globe Newswire)

EQNX::TICKER_START (NASDAQ:AZN),(Nasdaq First North Sweden:AZN.ST),(LSE:AZN.L), EQNX::TICKER_END Accumulus Synergy, a nonprofit organization working to develop an information and data exchange platform aimed at transforming how drug innovators and...(Globe Newswire)

EQNX::TICKER_START (HKSE:2518),(NYSE:ATHM),(NasdaqGM:LIZI),(NasdaqGM:QH),(NYSE:KUKE),(Other OTC:CLCGY),(Boerse Berlin - Freiverkehr:BOSS),(Other OTC:BOSSY),(HKSE:0142),(NYSE:FPAFY),(LSE:TPK),(Other...(Globe Newswire)

High-level results from the DELIVER Phase III trial showed AstraZeneca's FARXIGA (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or worsening...(BusinessWire)

--Based on ground-breaking DESTINY-Breast03 results showing ENHERTU reduced the risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1) AstraZeneca and Daiichi Sankyo's ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) has been...(BusinessWire)

Positive high-level results from the open-label Phase III CHAMPION-NMOSD trial showed that ULTOMIRIS(R) (ravulizumab-cwvz) achieved a statistically significant and clinically meaningful reduction in the risk of relapse in adults with...(BusinessWire)

AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, has been accepted and granted Priority Review in the US for patients with locally advanced or metastatic...(BusinessWire)

--ULTOMIRIS showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks ULTOMIRIS(R) (ravulizumab-cwvz) has been approved in the US for the treatment of adult...(BusinessWire)

--ENHERTU has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers AstraZeneca and Daiichi Sankyo's ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) has been granted...(BusinessWire)